



Universiteit
Leiden
The Netherlands

Systemic Upregulation of IL-10 (Interleukin-10) Using a Nonimmunogenic Vector Reduces Growth and Rate of Dissecting Abdominal Aortic Aneurysm

Adam, M.; Kooreman, N.G.; Jagger, A.; Wagenhauser, M.U.; Mehrkens, D.; Wang, Y.M.; ... ; Tsao, P.S.

Citation

Adam, M., Kooreman, N. G., Jagger, A., Wagenhauser, M. U., Mehrkens, D., Wang, Y. M., ... Tsao, P. S. (2018). Systemic Upregulation of IL-10 (Interleukin-10) Using a Nonimmunogenic Vector Reduces Growth and Rate of Dissecting Abdominal Aortic Aneurysm. *Arteriosclerosis, Thrombosis, And Vascular Biology*, 38(8), 1796-1805. doi:10.1161/ATVBAHA.117.310672

Version: Not Applicable (or Unknown)

License: [Leiden University Non-exclusive license](#)

Downloaded from: <https://hdl.handle.net/1887/87153>

Note: To cite this publication please use the final published version (if applicable).

DOI 10.1161/ATVBAHA.117.310672.

Click [Here](#) to view the article.

Systemic upregulation of IL-10 using a non-immunogenic vector reduces abdominal aortic aneurysm growth and dissection rate

Matti Adam^{1,2,3,*}, Nigel Kooreman^{1,4*}, Ann Jagger^{1,3}, Markus U. Wagenhaeuser^{1,3}, Dennis Mehrkens², Yongming Wang¹, Yosuke Kayama^{1,3}, Kensuke Toyama^{1,3}, Uwe Raaz^{1,3,5}, Isabel N. Schellinger^{1,3}, Lars Maegdefessel^{1,6}, Joshua M. Spin^{1,3}, Jaap F. Hamming⁴, Paul H.A. Quax⁴, Stephan Baldus², Joseph C. Wu¹, Philip S. Tsao^{1,3,#}

¹ Division of Cardiovascular Medicine and Cardiovascular Institute, Stanford University School of Medicine, Stanford, CA 94305, USA

² University of Cologne, Department of Cardiovascular Medicine, University Heart Center and Cologne Cardiovascular Research Center, Cologne, Germany

³ VA Palo Alto Health Care System, Palo Alto, CA 94304, USA

⁴ Department of Vascular Surgery, Leiden University, The Netherlands

⁵ Heart Center, Georg-August-University Göttingen, Göttingen, Germany

⁶ Department of Medicine, Karolinska Institutet, Stockholm, Sweden

* authors contributed equally

corresponding author

Running title: AAA IL-10

Basic Research

Arteriosclerosis, Thrombosis, and Vascular Biology

Keywords: abdominal aortic aneurysm, vascular inflammation, cytokines, in vivo transfection

Word count: 5258, 6 figures, 0 tables

Corresponding author's contact information:

Philip S. Tsao, PhD
Associate Chief of Staff for Research and Development
Veterans Affairs Palo Alto Health Care System
3801 Miranda Avenue
Palo Alto, CA 94304
Phone: (650) 493-5000 x62991
email: ptsao@stanford.edu

Abstract

Objective: Recruitment of immunological competent cells to the vessel wall is a crucial step in formation of abdominal aortic aneurysms (AAA). Innate immunity effectors (e.g., macrophages), as well as mediators of adaptive immunity (e.g., T cells), orchestrate a local vascular inflammatory response. Interleukin-10 (IL-10) is an immune-regulatory cytokine with a crucial role in suppression of inflammatory processes. We hypothesized that an increase in systemic IL-10-levels would mitigate AAA progression.

Methods and Results: Using a single intravenous injection protocol, we transfected an IL-10 transcribing non-immunogenic minicircle (MC) vector into the Angiotensin II (AngII)-ApoE-/- infusion mouse model of AAA. IL-10 MC transfection significantly reduced average aortic diameter measured via ultrasound at day 28 from 166.1 ± 10.8 % (control) to 131.0 ± 5.8 % (IL-10 transfected). Dissecting AAA rates were reduced by IL-10 treatment, with an increase in dissection-free survival from 21.5% to 62.3%. Using flow cytometry of aortic tissue from MC IL-10 treated animals, we found a significantly higher percentage of CD4+/CD25+/Foxp3+ regulatory T cells, with fewer CD8+/GranzymeB+ cytotoxic T cells. Furthermore, isolated aortic macrophages produced less TNF- α , more IL-10 and were more likely to be MRC1- positive alternatively-activated macrophages. These results concurred with gene expression analysis of LPS-stimulated and AngII-primed human peripheral blood mononuclear cells.

Conclusions: Taken together, we provide an effective gene therapy approach to AAA in mice by enhancing anti-inflammatory and dampening pro-inflammatory pathways through minicircle-induced augmentation of systemic IL-10 expression.

Abbreviations:

AAA - abdominal aortic aneurysm
AngII - Angiotensin II
BLI - Bioluminescence imaging
CTL - Cytotoxic T cell
FOXP3 - forkhead box P3
GRZB - Granzyme B
IL-10 - Interleukin-10

IL-6 - Interleukin-6
MC - Minicircle
MRC1 - Mannose Receptor, C type 1
PBMC - Peripheral Blood Mononuclear Cell
SMC - Smooth muscle cell
TNFa - Tumor necrosis factor alpha
T_{reg} - Regulatory T cell

Introduction

Human abdominal aortic aneurysm (AAA) is defined as a pathologic dilatation that exceeds the normal diameter by 50%, or that has an antero-posterior diameter of over 30 mm. AAAs are a significant cause of morbidity and mortality in the United States and worldwide. The average incidence in Western civilizations is 0.4-0.67%¹. Although mortality numbers are slowly decreasing due to better endovascular and open surgical repair techniques as well as better risk factor management², AAAs still accounted for up to 10,000 deaths per year in the US in 2014, or approximately 3.1 deaths per 100,000 people³.

Infiltration of monocytes/macrophages, polymorphonuclear leukocytes (PMNs), and T- and B-lymphocytes mark the early phases of aneurysm development⁴. With further progression, a variety of cytokines, leukotrienes and immunoglobulins attract additional inflammatory cells and establish a local vascular inflammatory response. Matrix degeneration with disruption of local collagen and elastin follows, accompanied by smooth muscle cell (SMC) apoptosis in the aortic media, and ultimately leading to AAA expansion and rupture^{5,6}.

With vascular inflammation being one of the major initial hallmarks of AAA formation, mechanisms that dampen the immune response might be leveraged to prevent progressive tissue damage. Interleukin-10 (IL-10) is a well described anti-inflammatory cytokine, with a crucial role in suppression of inflammatory processes in diseases such as environmental allergy, asthma or inflammatory bowel disease. There is evidence that the immune-regulatory capacities of IL-10 might also be crucial in aneurysm development, as the IL-10-1082 'A' polymorphism (associated with lower IL-10 production⁷) is more common in patients with AAA⁸, and patients with this polymorphism are at an increased risk of developing AAA⁹. IL-10 plasma concentrations in patients with AAA are significantly decreased compared to matched patients with coronary artery disease¹⁰. Also, IL-10-knockout mice show increased susceptibility to Angiotensin II (AngII)-induced aortic aneurysm and aortic rupture¹¹. To our knowledge, no studies have to-date been conducted utilizing transgenic IL-10 animals.

IL-10 treatment has already been successfully performed in inflammatory bowel disease and glomerulosclerosis in rodents. However, recent studies have encountered major pitfalls. Intravenous or intraperitoneal injections of recombinant IL-10 need to be performed close to the time point of disease induction, or be repeated daily, due to IL-10's short plasma half-life¹²⁻¹⁴. In humans, outcomes in the treatment of inflammatory bowel disease did not demonstrate efficacy¹⁵. While disease-specific reasons for these limited results may exist, one major drawback is the lack of sufficient IL-10 bioavailability at the tissue of interest¹⁶.

To increase IL-10 bioavailability and to overcome IL-10 delivery issues, here we applied a non-viral minicircle transfection approach to the AngII-infusion-ApoE^{-/-} AAA model. Minicircles (MC) are episomal DNA vectors lacking a bacterial plasmid backbone. Due to their small size compared to standard plasmids, they display higher transfection efficiency and survival rate of the target cells. In addition, MC constructs sustain a higher expression rate of their harboring transgenes over a longer period of time. This, combined with their low immunogenicity, makes them intriguing vectors for gene therapy¹⁷⁻¹⁹.

Material and Methods

Materials and Methods are available in the online-only Data Supplement.

Results

To evaluate transfection efficacy of our intravenous MC injection approach, we first utilized minicircles expressing a firefly luciferase reporter construct (MC-Luc). MC-Luc was injected and subsequent bioluminescence imaging (BLI) was performed at days 1, 3, 9, and 15. We found a noticeable increase in luciferase activity in regions corresponding to the lungs at 1-3 days after transfection, with increasing activity in the liver and kidney regions over the course of the first 9 days (Fig. 1A). By 15 days after transfection, the luciferase signal had significantly dropped, indicating a considerable loss of activity (Fig. 1B).

AngII-treatment began at day 7 after MC transfection, to ensure active vector expression during aneurysm induction. We also evaluated IL-10 plasma levels of mice at 7

and 14 days after injection with MC IL-10 or MC control, confirming expression and production of IL-10 in a similar fashion to MC-Luc. We found a significant increase in plasma IL-10 levels in MC IL-10-treated mice (vs. matched controls) at day 7 after transfection (161.3 ± 14.6 pg/ml vs. 55.5 ± 15.4 pg/ml, $p < 0.01$, $n=5$, Figure 1C). At day 14 after MC injection, no differences could be found for IL-10 expression in MC IL-10 vs. MC control (46.8 ± 13.4 pg/ml vs. 36.8 ± 10.6 pg/ml, $p = \text{n.s.}$, $n=4/5$). To further evaluate the long-term effects of MC IL-10 injection regarding tissue levels of IL-10, expression in peripheral tissues were quantified with qRT-PCR at day 28 after AngII infusion. Here, IL-10 did not show significantly higher expression in aortic tissue, lung tissue or hepatic tissue in comparison to MC control (Figure 1D). Interestingly however, splenic IL-10 expression was significantly higher in MC IL-10 than in controls (2.52 ± 0.5 -fold increase vs. MC control, $p < 0.01$, $n=10$). This was accompanied by higher splenic Foxp3 expression at day 28 after AngII (1.9 ± 0.3 -fold, $p < 0.05$, $n=10$, Fig. 1E), but not increased TNF levels.

Subcutaneous AngII pump implantation at day 7 after transfection led to significant suprarenal aortic aneurysm formation in ApoE^{-/-} mice as previously described²⁰, with 78% of the mice having a diameter of more than 150% of baseline in the control group. Aneurysm formation was attenuated in mice that had been injected with MC IL-10, as only 10% of these animals had a diameter increase of $\geq 150\%$ (average diameter 166.1 ± 10.8 % in control vs. 131.0 ± 5.8 % in IL-10 treated animals, $p < 0.01$, $n = 9$ vs. 10, Figure 2A). Differences in diameter remained throughout the time course of aneurysm formation, starting at day 7 (Fig. 2A). These findings were supported by H&E and Picrosirius Red stainings, which showed a relevant decrease in AAA diameter after MC IL-10 treatment (Figure 2B).

In the murine ApoE^{-/-} AngII infusion AAA model, aneurysm formation is typically driven by intramural hematoma or myointimal dissection of the aortic wall. Therefore, in addition to aneurysm size, the presence of a 'dissecting AAA' is an important aspect of AAA formation²¹. In concert with the significantly decreased diameter after MC IL-10 treatment, we found improved dissecting AAA-free survival in animals transfected with the IL-10 vector (21.5 % vs. 62.3 % at day 28 in AngII vs. AngII MC-IL10, $p = 0.01$, $n = 41$, Fig. 2C).

Next, we evaluated the number and polarization of CD45⁺ / CD3⁺ lymphocytes and F4/80⁺ macrophages in suprarenal aortic tissue 7 days after aneurysm induction via flow cytometry. AngII MC IL-10-treated animals showed a significantly higher percentage of regulatory T cells (T_{reg} cells) than AngII-control or non-AngII-treated animals (CD4⁺/CD25⁺/Foxp3⁺, 1.8 ± 0.1 % of CD45⁺/CD3⁺ vs. 0.6 ± 0.08 % in AngII-control vs. 0.7 ± 0.05 % in non-AngII-animals, $p < 0.01$ vs. AngII-control and non-AngII, $n=5/6/5$ per group, Fig. 3A). In contrast, AngII-control treated animals had an increased percentage of cytotoxic T cells compared to AngII MC IL-10 or non-AngII treated mice (CD8⁺ / GranzymeB⁺, 3.9 ± 0.2 % of CD45⁺/CD3⁺ vs. 2.3 ± 0.3 % in AngII-control and 2.6 ± 0.3 % in non-AngII, $p < 0.01$ vs. AngII MC IL-10 and non-AngII, $n = 6/5/5$ per group, Fig. 3B). As a result, the T_{reg} cell to cytotoxic T cell ratio (CD4⁺/CD25⁺/FOXP3⁺ per CD8⁺/GranzymeB⁺) was highly and significantly increased in the AngII MC IL-10-treated animals (Fig. 3C).

We did not find a significant difference in absolute cell number in aortic tissue (CD4⁺ or CD8⁺ or CD3⁺/CD45⁺ or F4/80⁺ cells of single cells) between the three experimental groups, indicating that there was a difference in cell polarization, rather than cell number (Supp. Figure 2).

Peripheral blood quantification did not reveal significant differences in T cell polarization regarding T_{reg} and cytotoxic T cells. CD4⁺ cells were significantly more present in peripheral blood in AngII-treated animals, independent of MC IL-10 treatment (CD4⁺ of single cells, 2.2 ± 0.3 % in non-AngII-animals vs. 3.5 ± 0.4 % in AngII-control vs. 3.7 ± 0.4 % in AngII MC IL-10, $p < 0.01$ vs. non-AngII, $n=5/6/5$ per group, Supp. Fig. 3D)

F4/80-positive macrophages in suprarenal aortic tissue were more prone to Tumor necrosis factor alpha (TNF- α) production (38.6 ± 5.3 percent of F4/80⁺ cells) without MC IL-10 application than after transfection with IL-10 (20.0 ± 3 percent of F4/80⁺, $p < 0.05$, $n = 4/5/4$ per group, Fig. 4A), and also showed decreased IL-10 signal (3.9 ± 0.5 % of F4/80⁺ cells vs. 8.6 ± 1.6 % of F4/80⁺ cells, $p < 0.01$ vs. AngII-control, $n = 4/5/4$ per group, Fig. 4B). Notably, the increased TNF- α /IL-10 ratio in AngII-treated control animals was reversed with IL-10

transfection (Fig. 4C). Intriguingly, suprarenal aortic macrophages showed increased differentiation into the more anti-inflammatory M2-like phenotype with MC IL-10 treatment (19.4 ± 1.2 % of Mannose Receptor C type 1 (MRC1)+ over F4/80+ cells vs. 11.6 ± 1.9 % in AngII control, $p < 0.05$ vs. control, $n = 4/5/4$ per group, Fig. 4D).

To further investigate translational potential in human cells, we primed human PBMCs with AngII or AngII/IL-10 before stimulation with LPS and evaluated expression of inflammatory markers. There was a significant reduction in inflammatory gene expression with AngII/IL-10 vs. AngII alone for all markers except *FOXP3* (0.07 ± 0.01 vs. 0.31 ± 0.05 vs. 0.19 ± 0.04 relative expression vs. GAPDH in cells not primed with AngII vs. AngII primed cells vs. AngII/IL-10 treated cells, $p = 0.07$ vs. (+) AngII, $n = 9/18/19$, Fig. 5A). Granzyme B (*GRZB*)-expression was lower in AngII/IL-10 treated cells (0.19 ± 0.05 vs. 0.2 ± 0.02 vs. 0.14 ± 0.01 relative expression vs. GAPDH in cells with (-) AngII vs. (+) AngII vs. (+) AngII/IL-10, $p < 0.05$ vs. (+) AngII, $n = 9/18/19$, Fig. 5B), resulting in no significant change of *FOXP3* to *GRZB* ratio in AngII (+) vs. AngII (+) / IL-10 (0.47 ± 0.1 vs. 1.55 ± 0.25 vs. 1.48 ± 0.3 -fold, $p = \text{n.s.}$ vs. (+) AngII, $n = 9/18/19$, Fig. 5C).

Looking at macrophage markers revealed beneficial effects for (+) AngII/IL-10 vs. (+) AngII alone. TNF- α (TNF) expression dropped significantly with MC IL-10 treatment (0.15 ± 0.01 vs. 0.09 ± 0.03 vs. 0.004 ± 0.002 ; $p < 0.05$ vs. (+) AngII, $n = 9/18/19$, Fig. 6A). IL-10 expression was increased in (+) AngII / IL-10 (0.24 ± 0.03 vs. 0.36 ± 0.06 vs. 0.62 ± 0.12 ; $p < 0.05$ vs. (+) AngII, $n = 9/15/11$, Fig. 6B), resulting overall in a significantly decreased TNF- α to IL-10 ratio (0.62 ± 0.05 vs. 0.18 ± 0.07 vs. 0.01 ± 0.01 ; $p < 0.01$ vs. (+) AngII and vs. (-) AngII, $n = 6/14/11$, Fig. 6C). Markers of alternatively activated M2-macrophages, such as MRC1 (0.005 ± 0.001 vs. 0.005 ± 0.001 vs. 0.01 ± 0.002 ; $p < 0.05$ vs. (+) AngII, $n = 9/15/17$, Fig. 6D) and CD163 (1.04 ± 0.16 vs. 0.8 ± 0.09 vs. 39.92 ± 21.79 ; $p < 0.01$ vs. (+) AngII, $n = 9/18/11$, Fig. 6E) were significantly up-regulated. Conversely, IL-6 expression was reduced in cells that were treated with IL-10 (0.32 ± 0.08 vs. 0.37 ± 0.06 vs. 0.05 ± 0.01 ; $p < 0.01$ vs. (+) AngII and vs. (-) AngII, $n = 6/15/14$, Fig. 6F).

Discussion

Here, we show that systemic transfection with a non-immunogenic delivery method using IL-10 expressing minicircles is feasible and effective in a murine model of AAA disease. Plasma IL-10 levels were significantly increased at 1 week after transfection in Apo E-/- mice, and IL-10 induction significantly decreased aneurysm size and likelihood of suprarenal dissecting AAA formation. These beneficial effects upon aneurysm development were accompanied by a significant increase in T_{reg} cells and a decrease in cytotoxic T cells. Furthermore, local macrophages were more likely to differentiate into the alternatively activated M2-macrophages and express less TNF- α as well as more IL-10. Human PBMCs with IL-10 treatment after AngII-incubation showed ameliorated expression of differentiation markers Granzyme B (GZMB), TNF- α , MRC1, CD163 and IL-6, indicating possible translational potential in the application of IL-10.

One major IL-10-induced anti-inflammatory process in tissue is the induction of CD4+ CD25+ FOXP3+ T_{reg} cells²². In general, their mechanism of action also involves production of Interleukin-10 (IL-10) itself^{22,23}, providing a self-amplifying feedback loop, which we also identified. The induction of a subset of more anti-inflammatory macrophages by T_{reg} cells²⁴, particularly the so-called 'deactivated' M2c-macrophages which are believed to be important for tissue remodelling and matrix deposition, is also regulated by IL-10^{25,26}. In AAA disease, M2-macrophages are present in the later phases of development²⁷ and are involved in healing and prevention of further AAA growth. By contrast, activation and clonal expansion of CD8+ cytotoxic T cells induces cell damage and apoptosis potentially worsening AAA disease, if not properly regulated^{28,29}. As IL-10 has been shown to contribute to CD8+ cytotoxic T cell (CTL) expansion under certain conditions, we monitored the CD8+ GranzymeB+ CTL amount in tissue and calculated the ratio of T_{reg} / CTL ratio to further characterize the impact of IL-10 on the T cell population in the aortic wall.

Using the AngII-induced AAA model, we observed that systemic overexpression of IL-10 via single timepoint MC transfection led to aortic cell polarization into T_{reg} cells and anti-

inflammatory M2-macrophages expressing MRC1. These changes in adaptive and innate immune cell differentiation were associated with a clear reduction in aneurysm formation. We did not find a significant change in CD3+/CD45+, CD4+, CD8+ or macrophage cell number in aortic tissue after MC injection. Therefore, our results suggest a polarization effect, rather than a recruitment. Considering the limited expression period of the MC-delivered plasmids of, at most, 2 weeks with regard to IL-10 plasma levels (when compared to the four-week period of aneurysm development), it could be that this treatment might have sparked self-amplifying cascades and cell-cell interactions that maintain the anti-inflammatory response. At 28 days after aneurysm induction, only splenic tissue showed increased expression of IL-10 (Figure 1D). This was accompanied by higher Foxp3 expression, possibly indicating pronounced T_{reg} polarization (Figure 1E). This is especially intriguing, as flow cytometry analysis of spleens at day 7 after AngII showed significantly fewer CD4+ cells and a tendency towards fewer Foxp3-positive T_{reg} cells (Supp. Figure 4 A and D). This might indicate an initial mobilization of CD4+ cells from the spleen in response to AngII, a redistribution process to non-lymphoid tissue known to occur after recognition of certain antigens³⁰. Subsequently, splenic IL-10 and Foxp3 expression might increase again over the next 3 weeks if MC IL-10 expression had successfully induced anti-inflammatory processes in the aorta.

In patients with AAA, both the number and function of T_{reg} cells as well as the expression of FOXP3 are significantly decreased in peripheral blood^{31,32}, suggesting that the lack of T_{reg} immunomodulation may accelerate AAA formation. Indeed, adoptive transfer of T_{reg} cells to AngII-treated ApoE^{-/-} mice reduced AAA incidence and severity in a dose-dependent manner³³. Further, direct treatment with T_{reg} cells decreased macrophage number and the expression of pro-inflammatory cytokines in local aortic tissue. After T_{reg} treatment *in vitro*, macrophages had a more pronounced M2-like phenotype, consistent with previous reports^{24,26}. As such, the beneficial effects of T_{reg} cells are likely mediated via direct cell-cell contact as well as paracrine effects.

Yodoi et al.³⁴ demonstrated that expansion of Foxp3+ T_{reg} cells by IL-2 complex treatment resulted in a marked decrease in the incidence and mortality of AAA, and that this effect could be reversed by genetic depletion of Foxp3+ T_{reg} cells, further underlining the importance of T_{reg} cells in the prevention of aneurysm disease. Moreover, Zhou and colleagues³² further clarified the importance of IL-10 in mediating the beneficial effects of T_{reg} cells in AAA formation. Transfusion of T_{reg} cells from WT animals suppressed macrophage activation and reduced lesion macrophage and T cell counts in the murine AngII AAA model. However, this was not the case in mice that were infused with T_{reg} cells from IL-10^{-/-} animals, suggesting that the presence of IL-10 is imperative for cell-cell interaction of T_{reg} cells with the surrounding tissue. IL-10 has also been shown to be a crucial regulator of inflammation-matrix interaction, as T_{reg} cells from IL-10 competent mice suppress MMP-9 and MMP-13 activity more strongly than T_{reg} cells from IL-10^{-/-} mice³². Notably, IL-10^{-/-} mice show increased elastin degradation¹¹ and, T_{reg} treatment inhibits apoptosis of aortic wall cells in the AngII-induced aneurysm model³³. Our data support a critical role for the mediator IL-10 in prevention of AAA formation, and suggest that a transient increase in IL-10 might be sufficient to induce a critical mass of anti-inflammatory T_{reg} cells and regulatory macrophages at the site of lesion, thereby possibly decreasing AAA growth by positively modulating the inflammatory response, with potential downstream effects on extracellular matrix degradation and apoptosis via IL-10.

Recent work highlights the special considerations that need to be taken into account regarding the role of aortic dissection in the AngII-AAA model^{21,35}. Inflammatory cell infiltration tends to localize to sites of aortic dissection³⁶. It is believed that classical activation of macrophages induces vascular dissection, thereby promoting AAA formation at least in part by an IL-6 dependent mechanism³⁷. Our work suggests that re-adjusting the macrophage activation cascades using IL-10 treatment suppresses IL-6 as well as TNF- α expression and promotes MRC1 and CD163 transcription. The IL-10-induced increase in T_{reg} cells and the shift from classical to alternatively activated macrophages in aortic tissue is therefore likely to be an important mechanism in the prevention of dissecting AAA. We assume that our anti-inflammatory treatment primarily suppresses both micro- and macro-ruptures, as these hemorrhagic events are thought to drive AAA growth in the AngII-model. This is further

underscored by the early separation of our AAA diameter and dissecting AAA-free survival curves (Fig. 2 A and B) at day 7 with a subsequently similar growth rate.

In PBMCs from healthy controls stimulated with AngII, we observed minimal impact on inflammatory gene expression in the absence of IL-10 treatment. Our cells of interest, mainly monocytes/macrophages and T cells, all express receptors for AngII^{34,38,39} and should therefore be susceptible to AngII priming. However, effects of AngII on leukocytes appear to be context-sensitive^{38,40} and are difficult to duplicate *in vitro*⁴¹. We acknowledge that our understanding of AngII-induced effects on mononuclear cells is not complete, nevertheless, IL-10 treatment was beneficial after PBMCs were primed with AngII, supporting our main hypothesis that IL-10 initiates an anti-inflammatory and self-amplifying polarization towards T_{reg} cells and M2-macrophages.

There are limitations to our study. We applied the MC IL-10 vector systemically, once, and did not seek to control the site of expression nor the effect duration. It is possible that observed effects might be even stronger, and display less off-target impact if a more specific approach to the vasculature or immune cells had been chosen^{42,43}. Additionally, we cannot definitively conclude whether systemic or local increases of IL-10 are more important to prevent AAA formation, as the cellular changes we induced in aortic tissue were observed after systemic IL-10 delivery with an initial increase of plasma IL-10. With regard to clinical applicability and the known methodological shortcomings of cell-specific transfections, we deliberately chose this approach, intending to maintain translational potential and seeking to prove that MCs are feasible non-immunogenic vectors for the treatment of AAAs in this mouse model. We did not seek to provide deeper mechanistic insights as the interaction of IL-10 with lymphocytes and myeloid cells has been extensively studied before. While we do not provide hemodynamic data (such as blood pressure) in these animals, and therefore cannot exclude differences in MC-IL10 treated vs. non-MC-IL-10 treated animals, a recent publication suggests no prognostic value of hemodynamic markers on aneurysm growth⁴⁴. Also, initial characterization of the model did not show any alteration in arterial blood pressure after AngII infusion²⁰. The recently published prevention of blood pressure increase by continuous IL-10 infusion has only been shown in combination with significantly higher doses of AngII (90ng/min) and vastly higher IL-10 levels (0.5ng/min) when compared to our plasma IL-10 concentration⁴⁵.

In summary, we provide evidence that a one-time application of an IL-10 transcribing minicircle vector successfully limits aneurysm formation in a mouse model of AAA, while increasing regulatory T cells and alternatively activated macrophages in the aortic wall. IL-10 treatment of PBMCs partially recapitulated the anti-inflammatory effects of IL-10, indicating possible translational potential in humans.

Acknowledgments

We thank Prof. Mark Kay, Stanford, for kindly providing the technical background regarding the MC technology.

Sources of Funding:

This work was supported by research grants from the National Institute of Health (R01 HL105299 and R01 HL122939 to P.S. Tsao, R01 AI085575 and R01 HL093172 to J.C. Wu), the Department of Veterans Affairs (1I01BX002641-01A to P.S. Tsao), the Deutsche Forschungsgemeinschaft (AD 492/1-1 to M. Adam, WA 3583/2-1 to M.U. Wagenhäuser, RA 2179/1-1 to U. Raaz), the Boehringer Ingelheim Fonds and the International Scholarship for Medical Students, Medical School of the University Erlangen, Germany (both to I. N. Schellinger), the Banyu Fellowship Program by Banyu Life Science Foundation International (to K. Toyama) and the Stanford Cardiovascular Institute (to J.M. Spin).

Disclosures

None.

References

- 1 Nordon, I. M., Hinchliffe, R. J., Loftus, I. M. & Thompson, M. M. Pathophysiology and epidemiology of abdominal aortic aneurysms. *Nature reviews. Cardiology* **8**, 92-102, doi:10.1038/nrcardio.2010.180 (2011).
- 2 Schermerhorn, M. L. *et al.* Changes in abdominal aortic aneurysm rupture and short-term mortality, 1995-2008: a retrospective observational study. *Annals of surgery* **256**, 651-658, doi:10.1097/SLA.0b013e31826b4f91 (2012).
- 3 CDC. Centers for Disease Control and Prevention, National Center for Health Statistics. Underlying Cause of Death 1999-2015 on CDC WONDER Online Database, released December, 2016. Data are from the Multiple Cause of Death Files, 1999-2015, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. Accessed at <http://wonder.cdc.gov/ucd-icd10.html> on Oct 4, 2017 7:14:35 AM.
- 4 Thomas, M. *et al.* Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. *Circulation* **114**, 404-413, doi:10.1161/CIRCULATIONAHA.105.607168 (2006).
- 5 Kunieda, T. *et al.* Angiotensin II induces premature senescence of vascular smooth muscle cells and accelerates the development of atherosclerosis via a p21-dependent pathway. *Circulation* **114**, 953-960, doi:10.1161/CIRCULATIONAHA.106.626606 (2006).
- 6 Ailawadi, G. *et al.* Smooth muscle phenotypic modulation is an early event in aortic aneurysms. *The Journal of thoracic and cardiovascular surgery* **138**, 1392-1399, doi:10.1016/j.jtcvs.2009.07.075 (2009).
- 7 Turner, D. M. *et al.* An investigation of polymorphism in the interleukin-10 gene promoter. *European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics* **24**, 1-8 (1997).
- 8 Bown, M. J. *et al.* The interleukin-10-1082 'A' allele and abdominal aortic aneurysms. *Journal of vascular surgery* **46**, 687-693, doi:10.1016/j.jvs.2007.06.025 (2007).
- 9 McColgan, P., Peck, G. E., Greenhalgh, R. M. & Sharma, P. The genetics of abdominal aortic aneurysms: a comprehensive meta-analysis involving eight candidate genes in over 16,700 patients. *International surgery* **94**, 350-358 (2009).
- 10 Kadoglou, N. P. *et al.* Arterial stiffness and novel biomarkers in patients with abdominal aortic aneurysms. *Regulatory peptides* **179**, 50-54, doi:10.1016/j.regpep.2012.08.014 (2012).
- 11 Ait-Oufella, H. *et al.* Natural regulatory T cells limit angiotensin II-induced aneurysm formation and rupture in mice. *Arterioscler Thromb Vasc Biol* **33**, 2374-2379, doi:10.1161/atvbaha.113.301280 (2013).
- 12 Grool, T. A. *et al.* Anti-inflammatory effect of interleukin-10 in rabbit immune complex-induced colitis. *Scandinavian journal of gastroenterology* **33**, 754-758 (1998).
- 13 Rachmawati, H. *et al.* Intravenous administration of recombinant human IL-10 suppresses the development of anti-thy 1-induced glomerulosclerosis in rats. *PDA journal of pharmaceutical science and technology / PDA* **65**, 116-130 (2011).

- 14 Duchmann, R., Schmitt, E., Knolle, P., Meyer zum Buschenfelde, K. H. & Neurath, M. Tolerance towards resident intestinal flora in mice is abrogated in experimental colitis and restored by treatment with interleukin-10 or antibodies to interleukin-12. *European journal of immunology* **26**, 934-938, doi:10.1002/eji.1830260432 (1996).
- 15 Buruiana, F. E., Sola, I. & Alonso-Coello, P. Recombinant human interleukin 10 for induction of remission in Crohn's disease. *Cochrane database of systematic reviews (Online)*, CD005109, doi:10.1002/14651858.CD005109.pub3 (2010).
- 16 Marlow, G. J., van Gent, D. & Ferguson, L. R. Why interleukin-10 supplementation does not work in Crohn's disease patients. *World journal of gastroenterology : WJG* **19**, 3931-3941, doi:10.3748/wjg.v19.i25.3931 (2013).
- 17 Chen, Z.-Y., Riu, E., He, C.-Y., Xu, H. & Kay, M. A. Silencing of Episomal Transgene Expression in Liver by Plasmid Bacterial Backbone DNA Is Independent of CpG Methylation. *Molecular therapy : the journal of the American Society of Gene Therapy* **16**, 548-556 (2008).
- 18 Huang, M. *et al.* Novel Minicircle Vector for Gene Therapy in Murine Myocardial Infarction. *Circulation* **120**, S230-S237, doi:10.1161/circulationaha.108.841155 (2009).
- 19 Lijkwan, M. A. *et al.* Short hairpin RNA gene silencing of prolyl hydroxylase-2 with a minicircle vector improves neovascularization of hindlimb ischemia. *Human gene therapy* **25**, 41-49, doi:10.1089/hum.2013.110 (2014).
- 20 Daugherty, A., Manning, M. W. & Cassis, L. A. Angiotensin II promotes atherosclerotic lesions and aneurysms in apolipoprotein E-deficient mice. *The Journal of clinical investigation* **105**, 1605-1612, doi:10.1172/jci7818 (2000).
- 21 Trachet, B. *et al.* Dissecting abdominal aortic aneurysm in Ang II-infused mice: suprarenal branch ruptures and apparent luminal dilatation. *Cardiovascular research* **105**, 213-222, doi:10.1093/cvr/cvu257 (2015).
- 22 Saraiva, M. & O'Garra, A. The regulation of IL-10 production by immune cells. *Nature reviews. Immunology* **10**, 170-181, doi:10.1038/nri2711 (2010).
- 23 Steinke, J. W. & Lawrence, M. G. T-cell biology in immunotherapy. *Annals of Allergy, Asthma & Immunology* **112**, 195-199, doi:<http://dx.doi.org/10.1016/j.anai.2013.12.020> (2014).
- 24 Tiemessen, M. M. *et al.* CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. *Proceedings of the National Academy of Sciences* **104**, 19446-19451, doi:10.1073/pnas.0706832104 (2007).
- 25 Martinez, F. O. & Gordon, S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000prime reports* **6**, 13, doi:10.12703/P6-13 (2014).
- 26 Liu, G. *et al.* Phenotypic and functional switch of macrophages induced by regulatory CD4+CD25+ T cells in mice. *Immunology and cell biology* **89**, 130-142 (2011).
- 27 Rateri, D. L. *et al.* Prolonged Infusion of Angiotensin II in apoE^{-/-} Mice Promotes Macrophage Recruitment with Continued Expansion of Abdominal Aortic Aneurysm. *The American Journal of Pathology* **179**, 1542-1548, doi:<http://dx.doi.org/10.1016/j.ajpath.2011.05.049> (2011).
- 28 Lindeman, J. H. N., Abdul-Hussien, H., van Bockel, J. H., Wolterbeek, R. & Kleemann, R. Clinical Trial of Doxycycline for Matrix Metalloproteinase-9 Inhibition in Patients With an Abdominal Aneurysm: Doxycycline Selectively Depletes Aortic Wall Neutrophils and Cytotoxic T Cells. *Circulation* **119**, 2209-2216, doi:10.1161/circulationaha.108.806505 (2009).
- 29 Henderson, E. L. *et al.* Death of Smooth Muscle Cells and Expression of Mediators of Apoptosis by T Lymphocytes in Human Abdominal Aortic Aneurysms. *Circulation* **99**, 96-104, doi:10.1161/01.cir.99.1.96 (1999).

- 30 Bronte, V. & Pittet, Mikael J. The Spleen in Local and Systemic Regulation of Immunity. *Immunity* **39**, 806-818, doi:<http://dx.doi.org/10.1016/j.immuni.2013.10.010> (2013).
- 31 Yin, M. *et al.* Deficient CD4+CD25+ T Regulatory Cell Function in Patients With Abdominal Aortic Aneurysms. *Arteriosclerosis, Thrombosis, and Vascular Biology* **30**, 1825-1831, doi:10.1161/atvbaha.109.200303 (2010).
- 32 Zhou, Y. *et al.* Regulatory T cells in human and angiotensin II-induced mouse abdominal aortic aneurysms. *Cardiovascular research* **107**, 98-107, doi:10.1093/cvr/cvv119 (2015).
- 33 Meng, X. *et al.* Regulatory T Cells Prevent Angiotensin II–Induced Abdominal Aortic Aneurysm in Apolipoprotein E Knockout Mice. *Hypertension* **64**, 875-882, doi:10.1161/hypertensionaha.114.03950 (2014).
- 34 Yodoi, K. *et al.* Foxp3+ Regulatory T Cells Play a Protective Role in Angiotensin II–Induced Aortic Aneurysm Formation in Mice. *Hypertension* **65**, 889-895, doi:10.1161/hypertensionaha.114.04934 (2015).
- 35 Saraff, K., Babamusta, F., Cassis, L. A. & Daugherty, A. Aortic Dissection Precedes Formation of Aneurysms and Atherosclerosis in Angiotensin II-Infused, Apolipoprotein E-Deficient Mice. *Arteriosclerosis, Thrombosis, and Vascular Biology* **23**, 1621-1626, doi:10.1161/01.atv.0000085631.76095.64 (2003).
- 36 Cao, R. Y., Amand, T., Ford, M. D., Piomelli, U. & Funk, C. D. The Murine Angiotensin II-Induced Abdominal Aortic Aneurysm Model: Rupture Risk and Inflammatory Progression Patterns. *Frontiers in Pharmacology* **1**, 9, doi:10.3389/fphar.2010.00009 (2010).
- 37 Tieu, B. C. *et al.* An adventitial IL-6/MCP1 amplification loop accelerates macrophage-mediated vascular inflammation leading to aortic dissection in mice. *The Journal of clinical investigation* **119**, 3637-3651, doi:10.1172/JCI38308 (2009).
- 38 Yanagitani, Y. *et al.* Angiotensin II Type 1 Receptor–Mediated Peroxide Production in Human Macrophages. *Hypertension* **33**, 335-339, doi:10.1161/01.hyp.33.1.335 (1999).
- 39 Crowley, S. D. *et al.* A Role for Angiotensin II Type 1 Receptors on Bone Marrow-Derived Cells in the Pathogenesis of Angiotensin II–Dependent Hypertension. *Hypertension* **55**, 99-108, doi:10.1161/hypertensionaha.109.144964 (2010).
- 40 Crowley, S. D. *et al.* Stimulation of lymphocyte responses by angiotensin II promotes kidney injury in hypertension. *American Journal of Physiology - Renal Physiology* **295**, F515-F524, doi:10.1152/ajprenal.00527.2007 (2008).
- 41 Keidar, S., Heinrich, R., Kaplan, M., Hayek, T. & Aviram, M. Angiotensin II Administration to Atherosclerotic Mice Increases Macrophage Uptake of Oxidized LDL: A Possible Role for Interleukin-6. *Arteriosclerosis, Thrombosis, and Vascular Biology* **21**, 1464-1469, doi:10.1161/hq0901.095547 (2001).
- 42 Mayer, C. R., Geis, N. A., Katus, H. A. & Bekerredjian, R. Ultrasound targeted microbubble destruction for drug and gene delivery. *Expert opinion on drug delivery* **5**, 1121-1138, doi:10.1517/17425247.5.10.1121 (2008).
- 43 Sapet, C., Laurent, N., Bertosio, E., Bertuzzi, M. & Sicard, F. Targeted transfection of cells/tissue in vivo. (2012).
- 44 Prins, P. A. *et al.* Angiotensin-induced abdominal aortic aneurysms in hypercholesterolemic mice: role of serum cholesterol and temporal effects of exposure. *PLoS One* **9**, e84517, doi:10.1371/journal.pone.0084517 (2014).
- 45 Lima, V. V. *et al.* Interleukin-10 limits increased blood pressure and vascular RhoA/Rho-kinase signaling in angiotensin II-infused mice. *Life sciences* **145**, 137-143, doi:10.1016/j.lfs.2015.12.009 (2016).

Significance

Abdominal aortic aneurysms (AAA) are a common and lethal disease, and infiltration of innate and adaptive immune cells with subsequent vascular inflammation of the aortic wall is a hallmark of aneurysm development. By applying a non-viral strategy with a non-immunogenic vector (minicircle) to systemically overexpress interleukin-10 in a murine model of AAA, we significantly decreased aneurysm growth and size as well as rate of dissecting AAA. These relevant effects were accompanied by higher amounts of beneficial T_{reg} cells and alternatively activated, anti-inflammatory macrophages in local aortic tissue. Furthermore, local pro-inflammatory immune response was dampened with lower TNF- α production and fewer cytotoxic T cells. This work suggests a novel approach for the treatment of AAA, with translational potential.




Figure 1 Vector expression and efficiency in vivo

Bioluminescence imaging (BLI) was performed at days 1, 3, 9, and 15 after intravenous injection of MC-Luc. Subsequently, BLI was performed with the Xenogen In Vivo Imaging System with administration of D-Luciferin at a dose of 375 mg/kg of body weight.

A) Localization and intensity of bioluminescence.

B) Quantification of bioluminescence per organ

C) IL-10 plasma levels of mice at d7 after transfection with MC IL-10; n=5 per group, ** = p≤0.01.

D) Gene expression analysis (q-rtPCR) of IL-10 after 28days of AngII treatment in homogenized tissue

E) Gene expression of splenic tissue for IL-10, foxp3 and TNF at d28 after AngII infusion.




Figure 2 Aortic diameter and rate of dissecting AAAs after MC IL-10 transfection

Ultrasound measurements of ApoE^{-/-} mice after subcutaneous infusion of AngII (1 μ g/kg/min).

A) Aortic diameter in percent of baseline diameter over a time course of 28 days; n = 15 vs. 15, * = p $\leq$ 0.05, ** = p $\leq$ 0.01 vs. AngII MC control.

B) Representative H&E and Picrosirius Red staining of supraceliac aortic sections harvested d28 after AngII infusion.

C) Kaplan-Meier curve for freedom from dissecting AAA; n = 15 vs. 15, ** = p $\leq$ 0.01 vs. AngII MC control.




Figure 3 T lymphocyte presence and differentiation in aortic tissue

At day 7 after aneurysm induction (d14 after transfection with MC) aortic tissue was harvested, lysed and analyzed via flow cytometry to characterize T cell differentiation. A and B include representative flow cytometry graphs and histograms; n=4/5/4; n=5/6/5

A) Percentage of CD4+/CD25+/Foxp3 of CD45+/CD3+ cells in untreated animals, AngII-infused controls and AngII-infused/MC-IL10 transfected animals; ** = $p \leq 0.01$ vs. AngII, ## = $p \leq 0.01$ vs. untreated.

B) Percentage of CD8+/GranzymeB+ of CD45+/CD3+ cells; ** = $p \leq 0.01$ vs. AngII MC IL-10, ## = $p \leq 0.01$ vs. untreated.

C) Ratio of CD4+/CD25+/Foxp3 over CD8+/GranzymeB+ cell (T_{reg} to cytotoxic T cell ratio), ** = $p \leq 0.01$ vs. AngII, ## = $p \leq 0.01$ vs. untreated.




Figure 4 Macrophage presence and differentiation in aortic tissue

At day 7 after aneurysm induction (d14 after transfection with MC) aortic tissue was harvested, lysed and analyzed via flow cytometry to characterize macrophage differentiation markers. A, B, D include representative flow cytometry graphs and histograms; n=4/5/4

A) Percentage of TNF- α + of F4/80+ cells in untreated, AngII-infused, and AngII-infused/MC-IL10 transfected animals; * = $p \leq 0.05$ vs. AngII MC-IL10, # = $p \leq 0.05$ vs. untreated.

B) Percentage of IL-10+ of F4/80+ cells; ** = $p \leq 0.01$ vs. AngII

C) Ratio of TNF- α + over IL-10+ cells; * = $p \leq 0.05$ vs. AngII MC-IL10, # = $p \leq 0.05$ vs. untreated.

D) Percentage of MRC1+ of F4/80+ cells; * = $p \leq 0.05$ vs. AngII




Figure 5 T lymphocyte differentiation in human PBMCs after AngII priming and stimulation

Human PBMCs were isolated and primed with AngII or AngII/IL-10 for 24 hours before cells were activated with LPS (24h) to further evaluate gene expression of T cell characterizing markers; n=9/18/19

A) Relative expression of FOXP3 over GAPDH in unprimed, AngII-primed, and AngII/IL-10 primed PBMCs; ## = $p \leq 0.01$ vs. untreated; $p = 0.07$ in AngII IL-10 vs. AngII.

B) Relative expression of GranzymeB (GZMB) in unprimed, AngII, AngII/IL-10 PBMCs; * = $p \leq 0.05$ vs. AngII.

C) Ratio (relative expression) of FOXP3 over GRZB; * = $p \leq 0.05$ vs. AngII.




Figure 6 Macrophage differentiation in human PBMCs after AngII priming and stimulation

Human PBMCs were isolated and primed with AngII or AngII/IL-10 for 24 hours before cells were activated with LPS (24h) to further evaluate macrophage activation (n=9/18/19)

A) Relative expression of $TNF-\alpha$ (TNF) over GAPDH in unprimed, AngII-primed, and AngII/IL-10 primed PBMCs; ** = $p \leq 0.01$ vs. AngII.

B) Relative expression of IL-10 in unprimed, AngII, and AngII/IL-10 PBMCs; * = $p \leq 0.05$ vs. AngII.

C) Ratio (relative expression) of TNF over IL-10; ** = $p \leq 0.01$ vs. AngII, ## = $p \leq 0.01$ vs. unprimed

D) Relative expression of MRC1 in unprimed, AngII, and AngII/IL-10 PBMCs; ** = $p \leq 0.01$ vs. AngII.

E) Relative expression of CD163 in unprimed, AngII, and AngII/IL-10 PBMCs; ** = $p \leq 0.01$ vs. AngII.

F) Relative expression of IL-6 in unprimed, AngII, and AngII/IL-10 PBMCs; ** = $p \leq 0.01$ vs. AngII.